Last reviewed · How we verify
Malignant lymphoma, large B-cell, diffuse — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| MONJUVI | TAFASITAMAB-CXIX | MORPHOSYS US INC | B-lymphocyte antigen CD19 | |||
| Xmab5574 | tafasitamab | Morphosys Us Inc | B-lymphocyte antigen CD19 | 2020-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- MORPHOSYS US INC · 1 drug in Malignant lymphoma, large B-cell, diffuse
- Morphosys Us Inc · 1 drug in Malignant lymphoma, large B-cell, diffuse
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Malignant lymphoma, large B-cell, diffuse:
- Malignant lymphoma, large B-cell, diffuse treatment updates — RSS
- Malignant lymphoma, large B-cell, diffuse treatment updates — Atom
- Malignant lymphoma, large B-cell, diffuse treatment updates — JSON
Cite this brief
Drug Landscape (2026). Malignant lymphoma, large B-cell, diffuse — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-lymphoma-large-b-cell-diffuse. Accessed 2026-06-10.
Related
- Malignant lymphoma, large B-cell, diffuse full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing